IAPO Rec'd PCT/PTO 14 FEB 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

February 14, 2006

Form PTO-1390-MOD (REV 10-96)	ATTORNEY'S DOCKET NUMBER ON/4-32910B				
TRANSMITTAL LETTER TO DESIGNATED/ELECTED CONCERNING A FILING	U.S. APPLICATION NO. (If known, see 37 CFR 1				
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED			
PCT/EP2004/009099	13 August 2004 (13.08.04)	15 August 2003 (15.08.03)			
TITLE OF INVENTION					
2,4-PYRIMIDINEDIAMINES USEFUL IN	THE TREATMENT OF NEOPLASTIC I	DISEASES, INFLAMMATORY AND			
IMMUNE SYSTEM DISORDERS					
APPLICANT(S) FOR DO/EO/US					
GARCIA-ECHEVERRIA ET AL.					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. 2. 3.		This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.  This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.  This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay
4.	$\boxtimes$	examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5.	⊠	A copy of the International Application as filed (35 U.S.C. 371(c)(2))  a.  is transmitted herewith (required only if not transmitted by the International Bureau).  b.  has been transmitted by the International Bureau. (See Form PCT/IB/308)  c.  is not required, as the application was filed in the United States Receiving Office (RO/US).
6. 7.		A translation of the International Application was filed if the Office States Receiving Office (RO/OS).  A translation of the International Application into English (35 U.S.C. 371(c)(2)).  Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)).  a.  are transmitted herewith (required only if not transmitted by the International Bureau).  b.  have been transmitted by the International Bureau.  c.  have not been made; however, the time limit for making such amendments has NOT expired.
8. 9. 10.		A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(4)).  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
lten	ns 11	1. to 16. below concern document(s) or information included.
11.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12.		An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13.	$\boxtimes$	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.
14.	$\boxtimes$	An Application Data Sheet under 37 CFR 1.76.
15.		A substitute specification.
16.		A change of power of attorney and/or address letter.
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).
19.		A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).
20.	$\boxtimes$	Other items or information: Unsigned Declaration

EEUEN EU

U.S. APPLICATION TO THE FEB 2005 INTERNATIONAL APPLICATION NO. PCT/EP2004/009099

The following fees are submitted:

APPLICATION NO. PCT/EP2004/009099

CALCULATION SONLY

		007	PC	T/EP2004/009099			ON/	<b>4-329</b> 1	l0B		
The following fees are submitted:							CALCULATIONS PTO USE				
21. 🛭 Basi	1.   Basic national fee										
22. Examination	22. Examination Fee										
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)											
. All other situations								200			
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$  If International Search Report was prepared and provided to the Office \$400  All other situations											
TOTAL OF 21, 22 AND 23 =									\$	900	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.											
Total Sheets	Extra	sheets		ach additional 50 or			RATE				
278 - 100 =	178	/50 =	mereor (rour	d up to a whole num	iber)	<del> </del> x -	\$ 2	250	\$	1,000	
Surcharge of \$130 for furnishing the oath of declaration later than									\$	.,,,,,,	
months from the CLAIMS	earliest		onty date (37 ER FILED	CFR 1.492(e)).  NUMBER EXTR	- Δ		RATE				
Total claims		20	- 20 =	0	<del>``</del>	X		50	\$		
Independent cla		2	-3=	0				00	\$		
MULTIPLE DEP	ENDEN	T CLAIM(S)	(if applicable	)		+ \$		60	\$		
				TOTAL OF AB					\$	1,900	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).									\$		
SUBTOTAL =							\$	1,900			
Processing fee of \$130 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).							+	\$			
TOTAL NATIONAL FEE =							E =	\$	1,900	<del></del>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied											
by an appropriat	te cover	sheet (37 C	FR 3.28, 3.31	). \$40 per property				+	\$		
<u>-</u> -				то	TAL F	EES E	NCLOSE	D =	\$	1,900	
										mount to efunded	\$
										charged	\$
a. 🔲 A chec	a. A check in the amount of \$ to cover the above fees is enclosed.										
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,900 to cover the above fees. A duplicate copy of this form is enclosed.											
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.											
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
Send all correspondence to the address associated with Customer No. 001095, which is currently:											
Novartis Attorney for Applicants						(	1				
Corporate Intellectual Property Reg. No. 36,214 One Health Plaza, Building 104 (862) 778-7898 East Hanover, NJ 07936-1080											